コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 y to CMV and vaccinia virus (previous DryVax smallpox vaccination).
2 to measure T cells elicited after childhood smallpox vaccination.
3 s with preexisting immunity to vaccinia from smallpox vaccination.
4 V/MPXV-specific CD8(+) T cells decades after smallpox vaccination.
5 accinated individuals had received childhood smallpox vaccination.
6 while remaining elevated in those with prior smallpox vaccination.
7 atients had a self-reported prior history of smallpox vaccination.
8 xviruses, notably vaccinia virus (VACV) from smallpox vaccination.
9 wever, excludes all individuals with AD from smallpox vaccination.
10 tibody immunity in individuals with no prior smallpox vaccination.
11 entially lethal complication associated with smallpox vaccination.
12 now that populations do not receive routine smallpox vaccination.
13 origins and diversity of the viruses used in smallpox vaccination.
14 lular immunity in subjects following primary smallpox vaccination.
15 ccount for differences in immune response to smallpox vaccination.
16 d areas, male gender, age < 15, and no prior smallpox vaccination.
17 ing to blindness is a severe complication of smallpox vaccination.
18 als who experienced adverse events following smallpox vaccination.
19 reviously assessed for clinical responses to smallpox vaccination.
20 udies focusing on CD4(+) T cell responses to smallpox vaccination.
21 likelihood of the development of fever after smallpox vaccination.
22 ightened the interest in the reinitiation of smallpox vaccination.
23 lay a role in ischemic events observed after smallpox vaccination.
24 potentially be maintained for decades after smallpox vaccination.
25 une individuals at 13, 29 and 48 years after smallpox vaccination.
26 ukemia and inadvertent autoinoculation after smallpox vaccination.
27 sCD40L did not significantly increase after smallpox vaccination.
28 atients with chest pain within 30 days after smallpox vaccination.
29 to measure T cells elicited after childhood smallpox vaccination.
30 of illness may be affected by age and prior smallpox vaccination.
31 dest clinical course had previously received smallpox vaccination.
32 reatment regimens against complications from smallpox vaccination.
33 embers and DoD civilian workers eligible for smallpox vaccination.
34 esponses to nonvaccinia OPXV infections from smallpox vaccination.
35 iated cardiac myocyte necrosis shortly after smallpox vaccination.
36 in vaccinia-naive adult volunteers following smallpox vaccination.
37 virus vaccine complications that occur from smallpox vaccination.
38 ed an expected adverse event associated with smallpox vaccination.
39 gnited a debate about whether to reintroduce smallpox vaccination.
40 of antiviral immunity induced by one or more smallpox vaccinations.
41 Prevention estimated rate of death owing to smallpox vaccination (1 in 1,000,000), and many failed t
43 In 5.5 months, the DoD administered 450 293 smallpox vaccinations (70.5% primary vaccinees and 29.5%
45 nting with chest pain 4 to 30 days following smallpox vaccination and be aware of the implications as
46 sk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the
48 ency, attributed in part to the cessation of smallpox vaccination and concomitant waning of populatio
49 4, 2003, a US Army soldier received primary smallpox vaccination and experienced a primary uptake re
50 s followed by Dryvax increases the safety of smallpox vaccination, and they highlight the importance
51 hat the levels of immunity induced following smallpox vaccination are comparable in magnitude to that
52 t 2.4% of the cohort would be ineligible for smallpox vaccination because of active skin disease in t
53 als with atopic dermatitis are excluded from smallpox vaccination because of their propensity to deve
54 roximately 50% of the US population received smallpox vaccinations before routine immunization ceased
55 studies have shown long-term immunity after smallpox vaccination, but skepticism remains as to wheth
56 dentifying dermatologic contraindications to smallpox vaccination by relying only on a self-reported
58 , declining cross-protection from historical smallpox vaccination campaigns, and persistent zoonotic
63 ely beneficial in myopericarditis related to smallpox vaccination, compared with other types of myope
66 A-BN vaccinees with and without a history of smallpox vaccination demonstrated detectable MPXV-specif
68 myo/pericarditis was observed during the US smallpox vaccination (DryVax) campaign initiated in 2002
70 sting of Singaporeans who received childhood smallpox vaccination found anti-vaccinia IgG binding and
72 ccinia virus (VV) infection, mimicking human smallpox vaccination, greatly increased expression of th
73 terrorism, dermatologist knowledge regarding smallpox vaccination has not been extensively examined.
75 zed that individuals who develop fever after smallpox vaccination have genetically determined differe
76 ith a confirmed diagnosis were demographics, smallpox vaccination, HIV status, exposure to someone wi
77 factor (IRF1) were associated with AEs after smallpox vaccination in 2 independent study samples.
79 estimated the effectiveness of postexposure smallpox vaccination in preventing or modifying disease
80 is among others; historical complications of smallpox vaccination, including postvaccinal encephalomy
83 e assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies
85 ential use of smallpox virus as a bioweapon, smallpox vaccination is currently being reintroduced.
86 prompts the question of whether cessation of smallpox vaccination is driving the phenomenon, and if s
87 acaques and have demonstrated that, although smallpox vaccination is safe in immunodeficient macaques
91 is increasing due to the absence of routine smallpox vaccination leading to a higher proportion of n
94 es, and long-lasting durability of childhood smallpox vaccination-mediated immune responses, includin
95 ant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit asse
97 ited by mpox infection (n = 5; n = 3 PWH) or smallpox vaccination (n = 17; all PWH) in a cohort of me
98 Eczema vaccinatum (EV) is a complication of smallpox vaccination occurring in patients with atopic d
103 e that, in addition to the CD8 response, the smallpox vaccinations raised a robust CD4 response with
107 th century, the method, source and origin of smallpox vaccinations remained unstandardised and opaque
108 ression changes in 197 recipients of primary smallpox vaccination representing the extremes of humora
110 Eczema vaccinatum (EV) is a complication of smallpox vaccination that can occur in persons with ecze
113 Specific recommendations are made regarding smallpox vaccination, therapy, postexposure isolation an
114 agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk t
115 to reveal the evolutionary relationships of smallpox vaccination viruses within the poxviruses as a
118 , 18 cases of probable myopericarditis after smallpox vaccination were reported (an incidence of 7.8
120 ivity against vaccinia virus, as a result of smallpox vaccination, which may limit its use as a vecto
123 has been a rare or unrecognized event after smallpox vaccinations with the New York City Board of He
124 cases of myopericarditis per million primary smallpox vaccinations with this strain of vaccinia virus
125 V) related to MPXV) and cessation of routine smallpox vaccination (with the live OPXV vaccinia), ther
126 as remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses th